Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07583953 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.
Trial Details
NCT Number NCT07583953
Lead Sponsor Suzhou Abogen Biosciences Co., Ltd.
Collaborators: The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Solid Tumors
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov